Q1 2026 · 13F-HR
Finepoint Capital LPholdings as filed
Filed 2026-05-14 · accession 0000904454-26-000285
$1.95B
Reported value
9
Positions
2026-03-31
Period end
The Brief · Finepoint Capital LP · Q1 2026
AI · grounded in 13F
Finepoint Capital LP established a new position in SOXX valued at $483.1M. The fund also opened a new position in QQQ for $366.4M and increased its stake in RXO by 7.29%. These additions coincided with the closure of its position in IWM, representing a $398M reduction. Additionally, the fund trimmed its holdings in QXO and SPY by 34.56% and 32.96% respectively.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $685.9M | 35.1% | 1,054,700 | PUT | SOLE |
| 464287523 | SOXX | ISHARES TR | $483.1M | 24.7% | 1,469,968 | PUT | SOLE |
| 46090E103 | QQQ | INVESCO QQQ TR | $366.4M | 18.8% | 634,755 | PUT | SOLE |
| 82846H405 | QXO | QXO INC | $269.1M | 13.8% | 13,858,415 | Common | SOLE |
| 74982T103 | RXO | RXO INC | $147.3M | 7.54% | 10,073,618 | Common | SOLE |
| 01444V111 | ANNAW | ALEANNA INC | $396,900 | 0.02% | 490,000 | Common | SOLE |
| 01444V103 | ANNA | ALEANNA INC | $229,774 | 0.01% | 27,717 | Common | SOLE |
| G6202B119 | MNYWW | MONEYHERO LIMITED | $76,075 | 0.00% | 895,000 | Common | SOLE |
| 320703408 | CLDI | CALIDI BIOTHERAPEUTICS INC | $249 | 0.00% | 1,042 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.